What is NDC 76282-718?

76282-718 is the product NDC for Lanreotide Acetate, Lanreotide acetate 60 mg/.2mL injection, listed with the FDA by EXELAN PHARMACEUTICALS, INC.. It has 1 package NDC, shown above in 10- and 11-digit form.

EXELAN PHARMACEUTICALS, INC., NDC labeler code 76282. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Lanreotide Acetate?

9 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Lanreotide Acetate NDC 76282-718 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)76282-718Labeler and product segments. Claims need a package NDC.

Product NDC at billing width76282-0718Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
76282-718-67	7628207186776282071867	1 POUCH in 1 CARTON (76282-718-67) / 1 SYRINGE in 1 POUCH / .2 mL in 1 SYRINGEMarketed from May 30, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lanreotide Acetate
Generic name (nonproprietary): lanreotide acetate
Active ingredients: Lanreotide acetate — 60 mg/.2mL
Dosage form: Injection
Route: Subcutaneous
Labeler: EXELAN PHARMACEUTICALS, INC.NDC labeler code 76282
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217193
Marketing start: May 30, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Somatostatin Receptor Agonists (Mechanism)
Identifiers: Product ID 76282-718_054af266-c850-45c8-b027-d810d7d5f0aeSPL ID 054af266-c850-45c8-b027-d810d7d5f0aeSPL set ID eec3c37e-83a7-4195-bccf-cd5973459eefRxCUI 749811, 749814, 749817UNII IEU56G3J9C
Pharmacologic class: Somatostatin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N476282071867 followed by a unit qualifier and the quantity

Package 76282-0718-67. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 1, 2025.

Indications (excerpt from the label)

Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 ) 1.1 Acromegaly Lanreotide Injection is indicated for the long-term treatment of acromegalic patients who have had an inadeq…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 76282-718

What is NDC 76282-718?: 76282-718 is the product NDC for Lanreotide Acetate, Lanreotide acetate 60 mg/.2mL injection, listed with the FDA by EXELAN PHARMACEUTICALS, INC.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Lanreotide Acetate.
What is the active ingredient?: Lanreotide acetate.
Who is the labeler?: EXELAN PHARMACEUTICALS, INC., NDC labeler code 76282. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Lanreotide Acetate?: 9 other product NDCs are listed under this name. See all Lanreotide Acetate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Lanreotide Acetate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Lanreotide Acetate	Lanreotide acetate 120 mg/.5mL	InjectionSubcutaneous	Amneal Pharmaceuticals LLC	70121-2517	70121-2517-05
Lanreotide Acetate	Lanreotide acetate 120 mg/.5mL	InjectionSubcutaneous	Cipla USA Inc.	69097-906	69097-0906-67
Lanreotide Acetate	Lanreotide acetate 60 mg/.2mL	InjectionSubcutaneous	Cipla USA Inc.	69097-907	69097-0907-67
Lanreotide Acetate	Lanreotide acetate 90 mg/.3mL	InjectionSubcutaneous	Cipla USA Inc.	69097-908	69097-0908-67
Lanreotide Acetate	Lanreotide acetate 90 mg/.3mL	InjectionSubcutaneous	EXELAN PHARMACEUTICALS, INC.	76282-719	76282-0719-67
Lanreotide Acetate	Lanreotide acetate 120 mg/.5mL	InjectionSubcutaneous	EXELAN PHARMACEUTICALS, INC.	76282-720	76282-0720-67
Lanreotide Acetate	Lanreotide acetate 120 mg/.5mL	InjectionSubcutaneous	Cipla USA Inc.	69097-870	69097-0870-67
Lanreotide Acetate	Lanreotide acetate 60 mg/.2mL	InjectionSubcutaneous	Cipla USA Inc.	69097-880	69097-0880-67
Lanreotide Acetate	Lanreotide acetate 90 mg/.3mL	InjectionSubcutaneous	Cipla USA Inc.	69097-890	69097-0890-67

Other NDCs under ANDA 217193

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217193
Product	Strength	Form · route	Labeler	Product NDC
Lanreotide Acetate	Lanreotide acetate 120 mg/.5mL	InjectionSubcutaneous	Cipla USA Inc.	69097-906
Lanreotide Acetate	Lanreotide acetate 60 mg/.2mL	InjectionSubcutaneous	Cipla USA Inc.	69097-907
Lanreotide Acetate	Lanreotide acetate 90 mg/.3mL	InjectionSubcutaneous	Cipla USA Inc.	69097-908
Lanreotide Acetate	Lanreotide acetate 90 mg/.3mL	InjectionSubcutaneous	EXELAN PHARMACEUTICALS, INC.	76282-719
Lanreotide Acetate	Lanreotide acetate 120 mg/.5mL	InjectionSubcutaneous	EXELAN PHARMACEUTICALS, INC.	76282-720